- Dr Kostourou's Lab received a international competitive grant from Worldwide Cancer Research to investigate novel anti-angiogenic treatments for cancer. More
- Fighting cancer: FAK levels do matter. In a study published today at Nature Communication (DOI: 10.1038/ncomms3020), Fleming researcher Vassiliki Kostourou and colleagues demonstrated that Focal Adhesion Kinase (FAK) has a dose dependent effect in tumour growth and angiogenesis. This work emphasizes the importance of anti-angiogenic treatment in combating cancer and show that the effects of FAK inhibitors as anti-cancer agents are more complex than anticipated. The significance of this study is highlighted by the distribution of a press release from the NPG press office. It is has been also highlighted in Nature.com web page. For more information please contact